Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Second Quarter 2025 Financial Results Conference Call and webcast.
Amicus Therapeutics Inc. (FOLD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 18,000,000 | $103,140,000 | -13% | 1.81% |
| 2. | Vestal Point Capital Ryan Wilder | 11,900,000 | $68,187,000 | +179% | 3.59% |
| 3. | Millennium Management Israel Englander | 7,421,640 | $42,525,997 | +121% | 0.02% |
| 4. | Perceptive Advisors Joseph Edelman | 7,412,830 | $42,475,516 | -66% | 1.57% |
| 5. | D E Shaw D. E. Shaw | 6,362,250 | $36,455,692 | +178% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.49 | 1,500 | $15,735.00 | 65,082 | 2021-11-01 | Filing | |
| $9.56 | 1,500 | $14,346.00 | 63,582 | 2021-10-01 | Filing | |
| $11.41 | 1,500 | $17,115.00 | 62,082 | 2021-09-01 | Filing | |
| $9.28 | 1,500 | $13,920.00 | 60,582 | 2021-08-02 | Filing | |
| $9.24 | 1,500 | $13,861.20 | 47,467 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.00 | 400 | $4,000.00 | 1,150,657 | 2025-02-19 | Filing | |
| $10.02 | 7,500 | $75,124.50 | 886,654 | 2024-12-02 | Filing | |
| $12.50 | 7,901 | $98,800.42 | 886,654 | 2024-11-06 | Filing | |
| $11.46 | 7,500 | $85,959.75 | 886,654 | 2024-11-01 | Filing | |
| $10.60 | 7,500 | $79,492.50 | 886,654 | 2024-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,407,588 | $168,505,480 | 0% | |
| 2. | 29,123,962 | $166,880,303 | 0.03% | |
| 3. | 27,532,209 | $157,759,558 | 0% | |
| 4. | 14,642,157 | $83,899,560 | 0.22% | |
| 5. | 11,568,097 | $66,285,196 | 0% |
News See All
Bank of America Securities Remains Bullish on Amicus Therapeutics (FOLD) With a $13 PT
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best strong buy stocks to buy under $10.
10 Best Strong Buy Stocks to Buy Under $10
He stated that there are a couple of factors behind this, including an improvement in trade, as more trade deals continue to be announced.
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
10 Best Small-Cap Stocks to Buy According to Billionaires
On Tuesday, the Dow Jones Industrial Average dropped 0.98%, mainly because of worries about rising US inflation and mixed earnings reports from big banks.
13 Best Healthcare Stocks to Buy Under $10
On June 27, Tiffany McGhee, CEO of Pivotal Advisors, appeared on CNBC to talk about the best course of action for investors amid current market dynamics.
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 25, Amicus Therapeutics, Inc.
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the best biotech stocks to invest in now.